Torl Bio
Culver City, US · 6 known investors
Find your way into Torl Bio
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibodies for cancer, including lead candidate TORL-1-23 targeting CLDN6 in ovarian cancer.
Founders & leadership
MA
Mark AllesNamed on SEC filing
MA
Mark AttanasioNamed on SEC filing
DL
David LicataNamed on SEC filing
NO
Neil O'BrienNamed on SEC filing
AS
Amit SinhaNamed on SEC filing
LS
Lynn SeelyNamed on SEC filing
DS
Dennis SlamonNamed on SEC filing
Investors · 6
Funding
SEC filings, press & company announcements$254.3M disclosed across 2 of 3 rounds · 2023–2025
▶$158.3MraisedApr 2024 · 52 investors · PharmaceuticalsRule 506(b)
▶$158.3MraisedApr 2024 · 52 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mark AllesExecutive Officer, Director
- Mark AttanasioDirector
- David LicataExecutive Officer, Director
- Neil O'BrienDirector
- Amit SinhaDirector
- Lynn SeelyDirector
- Dennis SlamonDirector
- Offering amount
- $158.3M
- Amount sold
- $158.3M
- First sale
- Apr 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Torl Bio do?
- TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibodies for cancer, including lead candidate TORL-1-23 targeting CLDN6 in ovarian cancer.
- Who are Torl Bio's investors?
- Torl Bio's investors include OCV Partners, RA Capital, Cowen Healthcare Investments, Goldman Sachs, Perceptive Xontogeny Venture, Vertex Ventures HC.
- How much funding has Torl Bio raised?
- Torl Bio has disclosed $254.3M raised across 2 of its 3 known rounds.
- Where is Torl Bio headquartered?
- Torl Bio is headquartered in Culver City, US.